Palladium Partners LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 1.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 174,240 shares of the company’s stock after selling 2,776 shares during the period. Johnson & Johnson makes up approximately 1.8% of Palladium Partners LLC’s portfolio, making the stock its 13th largest position. Palladium Partners LLC’s holdings in Johnson & Johnson were worth $23,051,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Lenox Wealth Advisors Inc. lifted its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the last quarter. Lbmc Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 0.4% during the 1st quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock worth $461,000 after purchasing an additional 14 shares during the last quarter. Stratford Consulting LLC lifted its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Stratford Consulting LLC now owns 2,728 shares of the company’s stock worth $361,000 after purchasing an additional 16 shares during the last quarter. North Point Portfolio Managers Corp OH lifted its position in shares of Johnson & Johnson by 0.7% during the 2nd quarter. North Point Portfolio Managers Corp OH now owns 2,923 shares of the company’s stock worth $387,000 after purchasing an additional 20 shares during the last quarter. Finally, Ironwood Investment Management LLC lifted its position in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Ironwood Investment Management LLC now owns 5,074 shares of the company’s stock worth $671,000 after purchasing an additional 20 shares during the last quarter. 65.93% of the stock is owned by institutional investors.

Several equities research analysts have recently issued reports on the stock. Vetr raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price objective for the company in a research report on Monday, October 30th. Citigroup Inc. lifted their price objective on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Jefferies Group LLC lifted their price objective on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Finally, Barclays PLC lifted their price objective on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and a consensus price target of $143.70.

Johnson & Johnson (NYSE:JNJ) opened at $139.76 on Tuesday. Johnson & Johnson has a one year low of $109.32 and a one year high of $144.35. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The stock has a market cap of $374,930.72, a PE ratio of 19.55, a PEG ratio of 2.84 and a beta of 0.82.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same period in the previous year, the business posted $1.68 earnings per share. The business’s revenue was up 10.3% compared to the same quarter last year. research analysts predict that Johnson & Johnson will post 7.28 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.40%. Johnson & Johnson’s dividend payout ratio (DPR) is 58.33%.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/14/palladium-partners-llc-sells-2776-shares-of-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.